Lacosamida Viso Farmacéutica

Lacosamide, the active ingredient in Lacosamida Viso Farmacéutica, is an anticonvulsant presented as a tablet for oral use. It is employed to treat partial‑onset seizures in patients with epilepsy and is indicated as adjunctive therapy when seizures are not adequately controlled by other medications.

GNH USA supplies Lacosamida Viso Farmacéutica as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union quality standards and is manufactured under GMP conditions. It is distributed through a validated cold‑chain logistics network to ensure product integrity.

Lacosamide is used in the management of focal epilepsy, acting as an adjunctive therapy to reduce seizure frequency. - Partial-onset seizures: reduces seizure frequency when added to existing antiepileptic regimens. - Adjunctive therapy for epilepsy: provides additional seizure control in patients whose seizures are not fully managed by other drugs. - Refractory focal epilepsy: may improve seizure control in patients resistant to standard treatments.

Lacosamide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Nausea - Fatigue

Serious or Rare Side Effects: - Suicidal thoughts or behavior - Severe skin reactions such as Stevens‑Johnson syndrome - Cardiac conduction abnormalities (e.g., PR interval prolongation) - Anaphylactic reactions

When prescribing lacosamide, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: dose adjustment may be required and renal function should be monitored. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Cardiac conduction: obtain baseline ECG and monitor for PR interval prolongation. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Concomitant CNS depressants: may increase sedation; monitor patient response. - Store at room temperature: keep in the original container, protect from moisture and light.

Lacosamide can interact with other medicines, affecting its plasma levels or increasing adverse effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lacosamide concentrations and risk of toxicity. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, oxcarbazepine): may lower lacosamide levels and reduce efficacy. - Other sodium channel blockers (e.g., carbamazepine, phenytoin): may enhance CNS depression and cardiac effects.

Moderate Interactions (Monitor Closely): - Concurrent antiepileptic drugs: may require dose adjustments based on therapeutic response. - Medications that prolong PR interval (e.g., digoxin, diltiazem): monitor ECG for additive effects. - Alcohol: may potentiate central nervous system depression.